Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies
Molecular Pharmaceutics · 03.06.2024 · 21 (6) · 2813-2827
DOI: 10.1021/acs.molpharmaceut.3c01223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 16.05.2024. Verfasst von Xianbing Dai und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, U.K. Hauptthemen laut MEDLINE: Psoriasis, Calcitriol, Rats, Sprague-Dawley, Needles. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Psoriasis, affecting 2-3% of the global population, is a chronic inflammatory skin condition without a definitive cure. Current treatments focus on managing symptoms. Recognizing the need for innovative drug delivery methods to enhance patient adherence, this study explores a new approach using calcipotriol monohydrate (CPM), a primary topical treatment for psoriasis. Despite its effectiveness, CPM's therapeutic potential is often limited by factors like the greasiness of topical applications, poor skin permeability, low skin retention, and lack of controlled delivery. To overcome these challenges, the study introduces CPM in the form of nanosuspensions (NSs), characterized by an average particle size of 211 ± 2 nm. These CPM NSs are then incorporated into a trilayer dissolving microneedle patch (MAP) made from poly(vinylpyrrolidone) and w poly(vinyl alcohol) as needle arrays and prefrom 3D printed polylactic acid backing layer. This MAP features rapidly dissolving tips and exhibits good mechanical properties and insertion capability with delivery efficiency compared to the conventional Daivonex ointment. The effectiveness of this novel MAP was tested on Sprague-Dawley rats with imiquimod-induced psoriasis, demonstrating efficacy comparable to the marketed ointment. This innovative trilayer dissolving MAP represents a promising new local delivery system for calcipotriol, potentially revolutionizing psoriasis treatment by enhancing drug delivery and patient compliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, U.K.
- School of Pharmacy, Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
- Faculty of Pharmacy, Universitas Hasanuddin, Makassar 90245, Indonesia.
- School of Chemistry and Chemical Engineering, Queen's University Belfast, David Keir Building, Stranmillis Road, Belfast BT9 5AG, U.K.
ORCID-Profile: Xianbing Dai, Andi Dian Permana, Alejandro J Paredes, Lalitkumar K Vora, Ryan F Donnelly
Zitieren
APA
Dai, X., Permana, A. D., Li, M., Habibie, Nur Amir, M., Peng, K., Zhang, C., Dai, H., Paredes, A. J., Vora, L. K., & Donnelly, R. F. (2024). Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies. Molecular Pharmaceutics, 21(6), 2813-2827. https://doi.org/10.1021/acs.molpharmaceut.3c01223
Vancouver
Dai X, Permana AD, Li M, Habibie, Nur Amir M, Peng K, et al. Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies. Molecular Pharmaceutics. 2024;21(6):2813-2827. doi:10.1021/acs.molpharmaceut.3c01223
BibTeX
@article{Dai2024,
author = {Dai, Xianbing and Permana, Andi Dian and Li, Mingshan and Habibie and Nur Amir, Muhammad and Peng, Ke and Zhang, Chunyang and Dai, Haodong and Paredes, Alejandro J and Vora, Lalitkumar K and Donnelly, Ryan F},
title = {Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {6},
pages = {2813--2827},
doi = {10.1021/acs.molpharmaceut.3c01223}
}
EUVIMED